Testicular cancer (TC) is the most common malignancy in young men and is highly curable with platinum-based chemotherapy. With growing survivorship rates, treatment-related symptom burden and quality of life (QoL) have become increasingly important. This study evaluates the impact of different TC treatments on symptom burden and QoL. MATERIAL AND
✦ The floor
Discussion
Signed responses from readers of the wire.
No direct change to audiology practice is warranted; however, audiologists treating patients on platinum-based chemotherapy should remain vigilant for monitoring ototoxicity, as treatment intensity may influence its severity.
Platinum-based chemotherapy is a known cause of ototoxicity, and understanding how treatment intensity modulates this risk could inform audiological monitoring protocols for oncology patients.
- 01Study examines QoL outcomes in metastatic testicular cancer patients on platinum-based chemotherapy.
- 02Ototoxicity (medication-related hearing damage) is a recognised side effect of platinum compounds.
- 03Higher treatment intensity may be associated with greater burden of side effects including hearing loss.
- 04Findings have peripheral relevance to audiologists involved in ototoxicity monitoring in oncology settings.
- 05Full audiology-specific outcome data not the primary focus of the study.
Treatment intensity affects quality of life in metastatic testicular cancer patients receiving platinum-based chemotherapy.
studyunclearPlatinum-based chemotherapy carries a risk of ototoxicity that may be influenced by treatment intensity.
studypartially supported- PMID
- 42338403
- DOI
- 10.1111/andr.70295.
- Journal
- Andrology
- Publication type
- research_article
- Evidence level
- 2b
- Population
- Patients with metastatic testicular cancer receiving platinum-based chemotherapy
- Intervention
- Varying intensities of platinum-based chemotherapy
- Comparator
- Lower vs. higher treatment intensity regimens
Primary outcomes
Quality of life; Treatment-related side effects including ototoxicity